These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 34836197)

  • 21. Prognostic and functional importance of the engraftment-associated genes in the patient-derived xenograft models of triple-negative breast cancers.
    Moon HG; Oh K; Lee J; Lee M; Kim JY; Yoo TK; Seo MW; Park AK; Ryu HS; Jung EJ; Kim N; Jeong S; Han W; Lee DS; Noh DY
    Breast Cancer Res Treat; 2015 Nov; 154(1):13-22. PubMed ID: 26438141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
    Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
    Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sulforaphene inhibits triple negative breast cancer through activating tumor suppressor Egr1.
    Yang M; Teng W; Qu Y; Wang H; Yuan Q
    Breast Cancer Res Treat; 2016 Jul; 158(2):277-86. PubMed ID: 27377973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
    Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
    J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional and genomic characterisation of a xenograft model system for the study of metastasis in triple-negative breast cancer.
    Johnstone CN; Pattison AD; Gorringe KL; Harrison PF; Powell DR; Lock P; Baloyan D; Ernst M; Stewart AG; Beilharz TH; Anderson RL
    Dis Model Mech; 2018 May; 11(5):. PubMed ID: 29720474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluating chemotherapeutic potential of soya-isoflavonoids against high penetrance genes in triple-negative breast cancer.
    Chatterjee P; Banerjee S
    J Biomol Struct Dyn; 2024 Sep; 42(15):8125-8144. PubMed ID: 37559513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genome-wide DNA methylation modified by soy phytoestrogens: role for epigenetic therapeutics in prostate cancer?
    Karsli-Ceppioglu S; Ngollo M; Adjakly M; Dagdemir A; Judes G; Lebert A; Boiteux JP; Penault-LLorca F; Bignon YJ; Guy L; Bernard-Gallon D
    OMICS; 2015 Apr; 19(4):209-19. PubMed ID: 25831061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
    Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
    Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epigenetic Switch-Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer.
    Deblois G; Tonekaboni SAM; Grillo G; Martinez C; Kao YI; Tai F; Ettayebi I; Fortier AM; Savage P; Fedor AN; Liu X; Guilhamon P; Lima-Fernandes E; Murison A; Kuasne H; Ba-Alawi W; Cescon DW; Arrowsmith CH; De Carvalho DD; Haibe-Kains B; Locasale JW; Park M; Lupien M
    Cancer Discov; 2020 Sep; 10(9):1312-1329. PubMed ID: 32546577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
    Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
    Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
    Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
    Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The EZH2- H3K27me3-DNMT1 complex orchestrates epigenetic silencing of the wwc1 gene, a Hippo/YAP pathway upstream effector, in breast cancer epithelial cells.
    Liu X; Li C; Zhang R; Xiao W; Niu X; Ye X; Li Z; Guo Y; Tan J; Li Y
    Cell Signal; 2018 Nov; 51():243-256. PubMed ID: 30121333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-κB pathway.
    Li T; Zhang Q; Zhang J; Yang G; Shao Z; Luo J; Fan M; Ni C; Wu Z; Hu X
    BMC Cancer; 2014 Feb; 14():96. PubMed ID: 24529079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model.
    Chiu HW; Yeh YL; Wang YC; Huang WJ; Ho SY; Lin P; Wang YJ
    Mol Cancer; 2016 Jun; 15(1):46. PubMed ID: 27286975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway.
    Wu HT; Lin J; Liu YE; Chen HF; Hsu KW; Lin SH; Peng KY; Lin KJ; Hsieh CC; Chen DR
    Phytomedicine; 2021 Jan; 81():153437. PubMed ID: 33352494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacotranscriptomic profiling of resistant triple-negative breast cancer cells treated with lapatinib and berberine shows upregulation of PI3K/Akt signaling under cytotoxic stress.
    Jabbarzadeh Kaboli P; Luo S; Chen Y; Jomhori M; Imani S; Xiang S; Wu Z; Li M; Shen J; Zhao Y; Wu X; Hin Cho C; Xiao Z
    Gene; 2022 Mar; 816():146171. PubMed ID: 35026293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.
    Rodríguez Bautista R; Ortega Gómez A; Hidalgo Miranda A; Zentella Dehesa A; Villarreal-Garza C; Ávila-Moreno F; Arrieta O
    Clin Epigenetics; 2018; 10():88. PubMed ID: 29983835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.
    Coussy F; de Koning L; Lavigne M; Bernard V; Ouine B; Boulai A; El Botty R; Dahmani A; Montaudon E; Assayag F; Morisset L; Huguet L; Sourd L; Painsec P; Callens C; Chateau-Joubert S; Servely JL; Larcher T; Reyes C; Girard E; Pierron G; Laurent C; Vacher S; Baulande S; Melaabi S; Vincent-Salomon A; Gentien D; Dieras V; Bieche I; Marangoni E
    Int J Cancer; 2019 Oct; 145(7):1902-1912. PubMed ID: 30859564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative phosphoproteomics reveals genistein as a modulator of cell cycle and DNA damage response pathways in triple-negative breast cancer cells.
    Fang Y; Zhang Q; Wang X; Yang X; Wang X; Huang Z; Jiao Y; Wang J
    Int J Oncol; 2016 Mar; 48(3):1016-28. PubMed ID: 26783066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. JAK2 regulates paclitaxel resistance in triple negative breast cancers.
    Han J; Yun J; Quan M; Kang W; Jung JG; Heo W; Li S; Lee KJ; Son HY; Kim JH; Choi J; Noh DY; Na D; Ryu HS; Lee C; Kim JI; Moon HG
    J Mol Med (Berl); 2021 Dec; 99(12):1783-1795. PubMed ID: 34626199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.